These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31860745)

  • 1. Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators.
    Mehta NA; Abdulsalam N; Kouides R; Ahmed H; Atif R; Shah A; Taylor S; Chuprun D; Huang D; Rao M
    Clin Cardiol; 2020 Mar; 43(3):260-266. PubMed ID: 31860745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    Clin Cardiol; 2017 Aug; 40(8):586-590. PubMed ID: 28333373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial recovery after cardiac resynchronization therapy in left bundle branch block-associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy.
    Wang NC; Hussain A; Adelstein EC; Althouse AD; Sharbaugh MS; Jain SK; Shalaby AA; Voigt AH; Saba S
    Ann Noninvasive Electrocardiol; 2019 Mar; 24(2):e12603. PubMed ID: 30267454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.
    Daimee UA; Vermilye K; Moss AJ; Goldenberg I; Klein HU; McNitt S; Zareba W; Kutyifa V
    Heart Rhythm; 2018 Sep; 15(9):1379-1386. PubMed ID: 29678779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital.
    Sinha AM; Bense J; Hohenforst-Schmidt W
    J Interv Card Electrophysiol; 2021 Nov; 62(2):401-407. PubMed ID: 33200285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter-Defibrillator Therapies.
    Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
    J Cardiovasc Pharmacol; 2019 May; 73(5):272-281. PubMed ID: 30747784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance.
    Champ-Rigot L; Gay P; Seita F; Benouda L; Morello R; Pellissier A; Alexandre J; Saloux E; Milliez P
    J Cardiovasc Magn Reson; 2020 Jun; 22(1):48. PubMed ID: 32580786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
    Skowasch D; Ringquist S; Nickenig G; Andrié R
    PLoS One; 2018; 13(3):e0194496. PubMed ID: 29566033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
    Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.
    Koene RJ; Menon V; Cantillon DJ; Dresing TJ; Martin DO; Kanj M; Saliba WI; Tarakji KG; Baranowski B; Hussein AA; Tchou PJ; Bhargava M; Callahan TD; Rickard JW; Niebauer MJ; Chung MK; Varma N; Wilkoff BL; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008168. PubMed ID: 32538135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.
    Zishiri ET; Williams S; Cronin EM; Blackstone EH; Ellis SG; Roselli EE; Smedira NG; Gillinov AM; Glad JA; Tchou PJ; Szymkiewicz SJ; Chung MK
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):117-28. PubMed ID: 23275233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.
    Duncker D; Haghikia A; König T; Hohmann S; Gutleben KJ; Westenfeld R; Oswald H; Klein H; Bauersachs J; Hilfiker-Kleiner D; Veltmann C
    Eur J Heart Fail; 2014 Dec; 16(12):1331-6. PubMed ID: 25371320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wearable Cardioverter-Defibrillators following Cardiac Surgery-A Single-Center Experience.
    Heimeshoff J; Merz C; Ricklefs M; Kirchhoff F; Haverich A; Bara C; Kühn C
    Thorac Cardiovasc Surg; 2019 Mar; 67(2):92-97. PubMed ID: 29925094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the wearable cardioverter-defibrillator - the Swiss experience.
    Kovacs B; Reek S; Sticherling C; Schaer B; Linka A; Ammann P; Brenner R; Krasniqi N; Müller AS; Dzemali O; Kobza R; Grebmer C; Haegeli L; Berg J; Mayer K; Schläpfer J; Domenichini G; Reichlin T; Roten L; Burri H; Eriksson U; Saguner AM; Steffel J; Duru F; Swiss Wcd Registry
    Swiss Med Wkly; 2020 Sep; 150():w20343. PubMed ID: 33035354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ
    Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.